While reading through Lilly’s earnings release, we were struck by several items. Having followed Lilly for over 20 years we remember a time long ago when their diabetes franchise appeared to be on the verge of extinction. Back then the company seemed to have lost their way while their rival Novo Nordisk was powering ahead. Today there is little doubt that Lilly has not just regained their mojo but is the undisputed leader in diabetes offering the most comprehensive portfolio of diabetes therapies.
Like Novo Lilly has also become more of a GLP-1 company than an insulin company . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.